DGIdb - ALDESLEUKIN Drug Record

ALDESLEUKIN chembl:CHEMBL1201438 ApprovedAntineoplasticImmunotherapy

Alternate Names:

HUMAN INTERLEUKIN-2
PROLEUKIN
INTERLEUKIN-2 ALDESLEUKIN
ALDESLEUKIN
INTERLEUKIN 2

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1992
FDA Approval	approved
Drug Class	recombinant protein
Drug Indications	antineoplastic agent

(1 More Sources)

Publications:

Shibata et al., 2007, Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations., Eur. J. Haematol.
Blank et al., 2006, The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells., J. Infect. Dis.
Stauber et al., 2006, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor., Proc. Natl. Acad. Sci. U.S.A.
Smyth et al., 2007, Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors., Blood
Fonseca et al., Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy., Scand. J. Immunol.
Lee et al., 2006, Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2., Oncol. Rep.
Steppan et al., 2006, Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog., J. Interferon Cytokine Res.
Maclennan et al., 2006, Airway inflammation in asymptomatic children with episodic wheeze., Pediatr. Pulmonol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Cornish et al., 2006, Differential regulation of T-cell growth by IL-2 and IL-15., Blood
Liu et al., 2006, [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]., Nan Fang Yi Ke Da Xue Xue Bao
Ouyang et al., 1999, Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes., Arch. Toxicol.
Recchia et al., 2003, Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy., J. Exp. Clin. Cancer Res.
Waldmann, 2007, Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma., Oncogene
Waldmann, 2007, Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey., J. Clin. Immunol.
Vlad et al., 2007, Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation., Transpl. Immunol.

ALDESLEUKIN IL2RB

Interaction Score: 27.82

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

PMIDs:
16596189 16542139 16477002 16617454 11752352 16569767

Sources:
TdgClinicalTrial ChemblInteractions TEND
ALDESLEUKIN IL2RG

Interaction Score: 24.73

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

PMIDs:
17598841 17083048 16477002 17363735 17635814

Sources:
TdgClinicalTrial ChemblInteractions TEND
ALDESLEUKIN IL2RA

Interaction Score: 5.33

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs:
16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources:
TdgClinicalTrial ChemblInteractions TEND
ALDESLEUKIN IL2

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TEND: ALDESLEUKIN
- Version: 01-August-2011
Alternate Names:

ALDESLEUKIN Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: ALDESLEUKIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class recombinant protein

FDA Approval approved

Publications:
TTD: Aldesleukin
- Version: 2020.06.01
Alternate Names:

D05PUD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201438
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201438
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Interleukin-2 receptor agonist
Direct Interaction	yes
Trial Name	Proleukin IL-2

Novel drug target	Established target
Trial Name	Proleukin IL-2
Mechanism of Interaction	Interleukin-2 receptor agonist

agonist (activating)
modulator

agonist (activating)
modulator

ALDESLEUKIN Drug Record

ALDESLEUKIN chembl:CHEMBL1201438 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

ALDESLEUKIN IL2RB

Interaction Types & Directionality: agonist (activating) modulator

Interaction Info: Mechanism of Interaction Interleukin-2 receptor agonist Direct Interaction yes Trial Name Proleukin IL-2

PMIDs: 16596189 16542139 16477002 16617454 11752352 16569767

Sources: TdgClinicalTrial ChemblInteractions TEND

ALDESLEUKIN IL2RG

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor agonist Direct Interaction yes Trial Name Proleukin IL-2

PMIDs: 17598841 17083048 16477002 17363735 17635814

Sources: TdgClinicalTrial ChemblInteractions TEND

ALDESLEUKIN IL2RA

Interaction Types & Directionality: agonist (activating) modulator

Interaction Info: Novel drug target Established target Trial Name Proleukin IL-2 Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs: 16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources: TdgClinicalTrial ChemblInteractions TEND

ALDESLEUKIN IL2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TEND: ALDESLEUKIN

Alternate Names: ALDESLEUKIN Primary Drug Name

Drug Info: Year of Approval 1992 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: ALDESLEUKIN

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class recombinant protein FDA Approval approved

Publications:

TTD: Aldesleukin

Alternate Names: D05PUD TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201438

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201438

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

PMIDs:
16596189 16542139 16477002 16617454 11752352 16569767

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor agonist

Direct Interaction yes

Trial Name Proleukin IL-2

PMIDs:
17598841 17083048 16477002 17363735 17635814

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

agonist (activating)

modulator

Interaction Info:

Novel drug target Established target

Trial Name Proleukin IL-2

Mechanism of Interaction Interleukin-2 receptor agonist

PMIDs:
16864089 10207608 16767920 11752352 17530023 17216565 17584597

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

ALDESLEUKIN Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class recombinant protein

FDA Approval approved

Alternate Names:

D05PUD TTD Drug ID